Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“We are the trial sponsor of COSMIC-021, and Roche is providing atezolizumab free of charge.”
FILING10-K0000939767-26-000021cik 0000939767
“We entered into a supply agreement with Ipsen to supply finished and labeled drug product for distribution in the territories outside of the U.S. and Japan for the term of the collaboration agreement as well as a quality agreement that provides respective quality responsibilities for the aforementioned supply.”
FILING10-K0000939767-26-000021cik 0000939767
“Natera will provide its Signatera™ assay to identify MRD+ for trial enrollment.”
FILING10-K0000939767-26-000021cik 0000939767
“To meet our obligations to regulatory authorities for the reporting of safety data from territories outside of the U.S. and Japan from sources other than our sponsored global clinical development trials, we rely on data collected and reported to us by Ipsen.”
FILING10-K0000939767-26-000021cik 0000939767
“The CRADA reflects a commitment by NCI-CTEP to provide funding for the broad exploration of cabozantinib's potential in a wide variety of cancers, each representing a substantial unmet medical need.”
FILING10-K0000939767-26-000021cik 0000939767
“To meet our obligations to regulatory authorities for the reporting of safety data from Japan from sources other than our sponsored global clinical development trials, we rely on data collected and reported to us by Takeda.”
FILING10-K0000939767-26-000021cik 0000939767
“Merck will fund one of these phase 3 studies and we will co-fund the phase 1/2 study and the other phase 3 study, as well as supply zanzalintinib and cabozantinib.”
FILING10-K0000939767-26-000021cik 0000939767
“To Ipsen, we granted the rights to develop and commercialize cabozantinib outside of the U.S. and Japan, and to Takeda we granted such rights in Japan.”
FILING10-K0000939767-26-000021cik 0000939767
“MINNEBRO® (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor, approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo.”
FILING10-K0000939767-26-000021cik 0000939767
“Collaboration services revenues were reduced by $22.8 million and $21.3 million for the years ended December 31, 2025 and 2024, respectively, to account for the 3% royalty we are required to pay Royalty Pharma on the net sales by Ipsen and Takeda of any product containing cabozantinib.”
FILING10-K0000939767-26-000021cik 0000939767
“In addition to the option deal with Sairopa, some of our active collaborations for biotherapeutics programs are with: • Adagene, which is focused on using Adagene's SAFEbody TM technology to develop novel masked ADCs or other innovative biotherapeutics with potential for improved therapeutic index; • Catalent, which is focused on the discovery and development of multiple ADCs using Catalent's proprietary SMARTag® site-specific bioconjugation technology; and • Invenra, which is focused on the discovery and development of novel binders and multispecific a ntibodies for the treatment of cancer.”
FILING10-K0000939767-26-000021cik 0000939767
“In addition to the option deal with Sairopa, some of our active collaborations for biotherapeutics programs are with: • Adagene, which is focused on using Adagene's SAFEbody TM technology to develop novel masked ADCs or other innovative biotherapeutics with potential for improved therapeutic index; • Catalent, which is focused on the discovery and development of multiple ADCs using Catalent's proprietary SMARTag® site-specific bioconjugation technology; and • Invenra, which is focused on the discovery and development of novel binders and multispecific a ntibodies for the treatment of cancer.”
FILING10-K0000939767-26-000021cik 0000939767
“In addition to the option deal with Sairopa, some of our active collaborations for biotherapeutics programs are with: • Adagene, which is focused on using Adagene's SAFEbody TM technology to develop novel masked ADCs or other innovative biotherapeutics with potential for improved therapeutic index; • Catalent, which is focused on the discovery and development of multiple ADCs using Catalent's proprietary SMARTag® site-specific bioconjugation technology; and • Invenra, which is focused on the discovery and development of novel binders and multispecific a ntibodies for the treatment of cancer.”
FILING10-K0000939767-26-000021cik 0000939767
“As part of our strategy to access clinical- or near-clinical-stage assets, we executed an exclusive option and license agreement and clinical development collaboration with Sairopa to develop ADU-1805.”
FILING10-K0000939767-26-000021cik 0000939767
Watchlist prices, news filtered to it, and its next report on your desk.
Prev close 56.88 · gapped below the open, then crossed back over prior close. High/low 57.54 at 5:15 pm ET, 55.29 at 9:45 am ET.
Exelixis, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Biological Products, (No Diagnostic Substances)
Exelixis, Inc. has 10 disclosed suppliers and 4 disclosed customers. Each one is named in an SEC filing, either Exelixis, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
EXEL (Exelixis, Inc.) has 10 disclosed suppliers and 4 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: ADAG −8.26%, in industrials & materials.